Home » Stocks » TMDX

TransMedics Group, Inc. (TMDX)

Stock Price: $23.77 USD -0.23 (-0.96%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $24.00 +0.23 (0.97%) Jan 22, 5:31 PM
Market Cap 645.61M
Revenue (ttm) 24.07M
Net Income (ttm) -31.61M
Shares Out 27.16M
EPS (ttm) -1.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $23.77
Previous Close $24.00
Change ($) -0.23
Change (%) -0.96%
Day's Open 23.89
Day's Range 23.28 - 24.50
Day's Volume 153,043
52-Week Range 10.50 - 24.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 week ago

TransMedics saw steady growth in 2019 after the public offering. Its transformative approach to organ transplantation has real benefits and seems to have traction as well, with Covid-19 only s...

PRNewsWire - 4 weeks ago

ANDOVER, Mass., Dec. 24, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients wi...

PRNewsWire - 1 month ago

ANDOVER, Mass., Dec. 23, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients wi...

Business Wire - 1 month ago

LONDON--(BUSINESS WIRE)--Deep Pharma Intelligence names Nanox Imaging (NASDAQ:NNOX), TransMedics, Inc. (NASDAQ: TMDX), Outset Medical, Inc. (NASDAQ:OM), Eargo, Inc. (NASDAQ:EAR), and Silk Road...

Other stocks mentioned: EAR, NNOX, OM, SILK
Zacks Investment Research - 1 month ago

Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.

Other stocks mentioned: MYO, XGN
Seeking Alpha - 2 months ago

TransMedics Group's (TMDX) CEO Waleed Hassanein on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

TransMedics (TMDX) delivered earnings and revenue surprises of 42.42% and 19.58%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 2 months ago

ANDOVER, Mass., Nov. 4, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients wit...

PRNewsWire - 2 months ago

ANDOVER, Mass., Oct. 29, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients wi...

Zacks Investment Research - 2 months ago

TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 3 months ago

ANDOVER, Mass., Oct. 21, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients wi...

GlobeNewsWire - 3 months ago

ANDOVER, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for pati...

GlobeNewsWire - 4 months ago

ANDOVER, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for pati...

Seeking Alpha - 5 months ago

TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

ANDOVER, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patie...

Zacks Investment Research - 5 months ago

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Other stocks mentioned: HCAT, RMD
Zacks Investment Research - 5 months ago

TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

ANDOVER, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patie...

GlobeNewsWire - 6 months ago

ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patie...

Seeking Alpha - 7 months ago

TransMedics: A Medical Device Company Creating A Healthy Ecosystem

The Motley Fool - 7 months ago

Shares slumped after the company announced it's raising capital.

GlobeNewsWire - 7 months ago

ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patien...

GlobeNewsWire - 7 months ago

ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patien...

GlobeNewsWire - 7 months ago

Primary Effectiveness and Safety Endpoints Were Met. The OCS Liver Achieved Statistical Superiority of The Primary Effectiveness Endpoint by Demonstrating Significant Reduction of Early Allogr...

Seeking Alpha - 8 months ago

TransMedics Group's (TMDX) CEO Waleed Hassanein on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 9 months ago

TransMedics Expects Strong 2020 Growth Trajectory

GlobeNewsWire - 10 months ago

ANDOVER, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for pati...

Seeking Alpha - 10 months ago

TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Disrupting Organ Transplants: TransMedics And In-Kind Competitors

Zacks Investment Research - 1 year ago

TransMedics (TMDX) successfully completes heart transplants from DCD donors, using its OCS technology.

The Motley Fool - 1 year ago

The current transportation process is riddled with inefficiencies and waste. TransMedics is on a mission to fix the problem and deliver huge returns for investors.

Seeking Alpha - 1 year ago

4 Reasons TransMedics Stock Is A Buy Right Now

GlobeNewsWire - 1 year ago

ANDOVER, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patie...

InvestorPlace - 1 year ago

The IPO market is on fire right now. But not all the new IPO stocks make for promising investing opportunities to say the least.

Other stocks mentioned: DTIL, FSLY, LEVI, UBER

About TMDX

TransMedics Group, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion apparatus, optimization, and monitoring syste... [Read more...]

Industry
Medical Devices
IPO Date
May 2, 2019
CEO
Dr. Waleed H. Hassanein
Employees
109
Stock Exchange
NASDAQ
Ticker Symbol
TMDX
Full Company Profile

Financial Performance

In 2019, TMDX's revenue was $23.60 million, an increase of 81.33% compared to the previous year's $13.02 million. Losses were -$33.55 million, 41.2% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is 19.20, which is a decrease of -19.23% from the latest price.

Price Target
$19.20
(-19.23% downside)
Analyst Consensus: Buy